Indian Pharma Stocks Drop Amid U.S. Generics Concerns

  Published 1 year ago

Indian pharma stocks fall as Macquarie warns of U.S. generics price erosion and downgrades key firms.

  • NIPHARM drops 1.5% as 17/20 Nifty 50 pharma stocks decline amid rising competition.
  • Macquarie cites easing U.S. drug shortages and increased competition accelerating price erosion.
  • Aurobindo, Cipla, Dr. Reddy's, Lupin downgraded; Q1 results at risk from gRevlimid competition.

You might like these

Dreamfolks Shares Drop as Adani Touts Fintech Impact

Tesla Sales Dip in Italy & Europe

Indian Markets Edge Up on GST Optimism

Lenovo & DreamWorks Expand Tech Partnership

PNB Shares Drop 2.5% Amid Citi Downgrade Alert

U.S. Inflation Rises Amid Tariffs, Fed Cautious

India PMI Shows Strong July Growth

News that matters the most ⚡